Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Molecular Pathology
  • View item
  • Home
  • ICR Divisions
  • Molecular Pathology
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Azacitidine and Durvalumab in First-line Treatment of Elderly Patients With Acute Myeloid Leukemia.

Thumbnail
View/Open
Accepted version (864.4Kb)
Date
2021-12-21
ICR Author
Taussig, David
Author
Zeidan, AM
Boss, IW
Beach, CL
Copeland, WB
Thompson, EG
Fox, BA
Hasle, VE
Hellmann, A
Taussig, D
Tormo, M
Voso, MT
Cavenagh, J
O'Connor, T
Previtali, A
Rose, S
Silverman, LR
Show allShow less
Type
Journal Article
Metadata
Show full item record
Abstract
Evidence suggests that combining immunotherapy with hypomethylating agents may enhance antitumor activity. This phase 2 study investigated the activity and safety of durvalumab, a programmed death ligand 1 (PD-L1) inhibitor, combined with azacitidine for patients aged ≥65 years with acute myeloid leukemia (AML), including analyses to identify biomarkers of treatment response. Patients were randomized to first-line therapy with azacitidine 75 mg/m2 on days 1-7 with (Arm A, n= 64) or without (Arm B, n=65) durvalumab 1500 mg on day 1 every 4 weeks. Overall response rate (complete response [CR] + CR with incomplete blood recovery [CRi]) was similar in both arms (Arm A, 31.3%; Arm B, 35.4%), as were overall survival (A, 13.0 months; B, 14.4 months) and duration of response (A, 24.6 weeks; B, 51.7 weeks; P=0.0765). No new safety signals emerged with combination treatment. The most frequently reported treatment-emergent adverse events were constipation (Arm A, 57.8%; Arm B, 53.2%) and thrombocytopenia (A, 42.2%; B, 45.2%). DNA methylation, mutational status, and PD-L1 expression were not associated with response to treatment. In this study, first-line combination therapy with durvalumab and azacitidine in older patients with AML was feasible, but did not improve clinical efficacy compared with azacitidine alone. ClinicalTrials.gov: NCT02775903.
URI
https://repository.icr.ac.uk/handle/internal/5115
DOI
https://doi.org/10.1182/bloodadvances.2021006138
https://doi.org/10.1182/bloodadvances.2021006138
 
Collections
  • Molecular Pathology
Research team
Acute Leukaemia
Language
eng
Date accepted
2021-11-24
License start date
2021-12-21
Citation
Blood advances, 2021

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.